﻿ ﻿﻿ Synthesis and characterization of new copper(II) complex with drimane thiosemicarbazone ligands
 Articolul precedent Articolul urmator 206 0 SM ISO690:2012BLAJA, Svetlana; LUNGU, Lidia; CIOCARLAN, Alexandru; SHOVA, Sergiu; ARICU, Aculina. Synthesis and characterization of new copper(II) complex with drimane thiosemicarbazone ligands. In: Achievements and perspectives of modern chemistry. 9-11 octombrie 2019, Chişinău. Chisinau, Republic of Moldova: Tipografia Academiei de Ştiinţe a Moldovei, 2019, p. 209. ISBN 978-9975-62-428-2. EXPORT metadate: Google Scholar Crossref CERIF BibTeXDataCiteDublin Core
Achievements and perspectives of modern chemistry 2019
Conferința "International Conference "Achievements and perspectives of modern chemistry""
Chişinău, Moldova, 9-11 octombrie 2019

 Synthesis and characterization of new copper(II) complex with drimane thiosemicarbazone ligands

Pag. 209-209

 Blaja Svetlana, Lungu Lidia, Ciocarlan Alexandru, Shova Sergiu, Aricu Aculina Institute of Chemistry Disponibil în IBN: 11 noiembrie 2019

Rezumat

Thiosemicarbazones have attracted attention for many years due to their pharmacological utility as therapeutic agents and versatility as ligands allowing them to give rise to a wide variety of coordination modes [1]. In this connection, we used in coupling reaction with tiosemicarbazide drimenone (2), which is the degradation product of commercially available sclareolide (1). The synthesis of the target compounds was done according to the Scheme:formulaReagents and conditions:a.NH2NHCSNH2, EtOH, delta, 24h, 83%; b.CuCl2·2H2O, MeOH, 50°C, 30 min,67%. SchemeAs starting material for the synthesis of named compounds lactone (1) was used, which was transformed in three steps in drimenone (2), with an 51% overall yield (Scheme) [2]. Drimenone (2) was coupled in ethanol with thiosemicarbazide in a molar ratio 1:1, to afford drimane thiosemicarbazone (3). Subsequently, the complexation of the ligand (3) with Cu(II) salt in the molar ratio 1,5:1 (L:M), was developed [3]. The structure of obtained compounds have been established using modern methods of analysis (ATR-FTIR, 1H, 13C and 15N NMR, MS and XRD). According to X-ray crystallography compound (4) crystalize in chiral P1 space group of triclinic system. The crystal has a molecular crystalline structure, the asymmetric part of which includes two asymmetric crystallographic complexes having the formula: [Cu4L6Cl4], where H3L is the neutral ligand (3). The hexanuclear cluster has an adamantanoid structure enhanced by four Cl- terminal ions and six molecule of (3) as bidentate ligands. Each copper atom has a S2Cl2 coordination having a weakly distorted tetrahedral geometry and an oxidation number +1. The positive charge of the copper atoms is offset by the negative charge of the four chlorine ions so that the load balance corresponds to the formula [Cu4L6Cl4].

### Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-87346</cfResPublId>
<cfResPublDate>2019</cfResPublDate>
<cfStartPage>209</cfStartPage>
<cfISBN>978-9975-62-428-2</cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/87346</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'><p>Synthesis and characterization of new copper(II) complex with drimane thiosemicarbazone ligands</p></cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Thiosemicarbazones have attracted attention for many years due to their pharmacological utility as therapeutic agents and versatility as ligands allowing them to give rise to a wide variety of coordination modes [1]. In this connection, we used in coupling reaction with tiosemicarbazide drimenone (2), which is the degradation product of commercially available sclareolide (1). The synthesis of the target compounds was done according to the Scheme:</p><p>formula</p><p>Reagents and conditions:a.NH2NHCSNH2, EtOH, delta, 24h, 83%; b.CuCl2&middot;2H2O, MeOH, 50&deg;C, 30 min,67%. Scheme</p><p>As starting material for the synthesis of named compounds lactone (1) was used, which was transformed in three steps in drimenone (2), with an 51% overall yield (Scheme) [2]. Drimenone (2) was coupled in ethanol with thiosemicarbazide in a molar ratio 1:1, to afford drimane thiosemicarbazone (3). Subsequently, the complexation of the ligand (3) with Cu(II) salt in the molar ratio 1,5:1 (L:M), was developed [3]. The structure of obtained compounds have been established using modern methods of analysis (ATR-FTIR, 1H, 13C and 15N NMR, MS and XRD). According to X-ray crystallography compound (4) crystalize in chiral P1 space group of triclinic system. The crystal has a molecular crystalline structure, the asymmetric part of which includes two asymmetric crystallographic complexes having the formula: [Cu4L6Cl4], where H3L is the neutral ligand (3). The hexanuclear cluster has an adamantanoid structure enhanced by four Cl- terminal ions and six molecule of (3) as bidentate ligands. Each copper atom has a S2Cl2 coordination having a weakly distorted tetrahedral geometry and an oxidation number +1. The positive charge of the copper atoms is offset by the negative charge of the four chlorine ions so that the load balance corresponds to the formula [Cu4L6Cl4].</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-52201</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-23821</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12404</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12182</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11130</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfStartDate>2019T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-52201</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-52201-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Blaja</cfFamilyNames>
<cfFirstNames>Svetlana</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-23821</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-23821-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Lungu</cfFamilyNames>
<cfFirstNames>Lidia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12404</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12404-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Ciocarlan</cfFamilyNames>
<cfFirstNames>Alexandru</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12182</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12182-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Shova</cfFamilyNames>
<cfFirstNames>Sergiu</cfFirstNames>
<cfFamilyNames>Шова</cfFamilyNames>
<cfFirstNames>Сергей</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11130</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11130-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2019T24:00:00</cfStartDate>
<cfFamilyNames>Aricu</cfFamilyNames>
<cfFirstNames>Aculina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>